2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Titel:
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Auteur:
Goldhirsch, Aron Gelber, Richard D Piccart-Gebhart, Martine J de Azambuja, Evandro Procter, Marion Suter, Thomas M Jackisch, Christian Cameron, David Weber, Harald A Heinzmann, Dominik Lago, Lissandra Dal McFadden, Eleanor Dowsett, Mitch Untch, Michael Gianni, Luca Bell, Richard Köhne, Claus-Henning Vindevoghel, Anita Andersson, Michael Brunt, A Murray Otero-Reyes, Douglas Song, Santai Smith, Ian Leyland-Jones, Brian Baselga, Jose